A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition

British Journal of Pharmacology

Volumn 169, Issue 5, 2013, Pages 1024-1034

  Kobayashi, Y ^a   Wada, H ^b   Rossios, C ^a   Takagi, D ^a   Charron, C ^a   Barnes, P J ^a   Ito, K ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b KYORIN UNIVERSITY   (Japan)

Author keywords

chronic obstructive pulmonary disease; corticosteroid insensitivity; histone deacetylase 2; macrolide; oxidative stress; phosphaoinositide 3 kinase; protein phosphatase 2A; solithromycin

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; DEXAMETHASONE; ERYTHROMYCIN; HISTONE DEACETYLASE; INTERLEUKIN 8; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; SOLITHROMYCIN; ANTIINFECTIVE AGENT; CORTICOSTEROID; HDAC2 PROTEIN, HUMAN; HISTONE DEACETYLASE 2; HYDROGEN PEROXIDE; IL8 PROTEIN, HUMAN; MACROLIDE; PHOSPHOPROTEIN PHOSPHATASE 2; SMOKE; TRIAZOLE DERIVATIVE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HORMONE RESISTANCE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEUTROPHILIA; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CULTURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; MONONUCLEAR CELL; NEUTROPHIL; SMOKE; TOBACCO; U937 CELL LINE;

ADRENAL CORTEX HORMONES; ANIMALS; ANTI-BACTERIAL AGENTS; CELLS, CULTURED; DEXAMETHASONE; DRUG RESISTANCE; HISTONE DEACETYLASE 2; HUMANS; HYDROGEN PEROXIDE; INTERLEUKIN-8; LEUKOCYTES, MONONUCLEAR; MACROLIDES; MALE; MICE, INBRED C57BL; NEUTROPHILS; OXIDATIVE STRESS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN PHOSPHATASE 2; PROTO-ONCOGENE PROTEINS C-AKT; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKE; TOBACCO; TRIAZOLES; TUMOR NECROSIS FACTOR-ALPHA; U937 CELLS;

EID: 84879019868     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12187     Document Type: Article

References (52)

1. Adenuga D, Yao H, March TH, Seagrave J, Rahman I, (2009). Histone deacetylase 2 is phosphorylated, ubiquitinated, and degraded by cigarette smoke. Am J Respir Cell Mol Biol 40: 464-473.
2. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Jr, Criner GJ, et al. (2011). Azithromycin for prevention of exacerbations of COPD. N Engl J Med 365: 689-698.
3. Alessi DR, Downes CP, (1998). The role of PI 3-kinase in insulin action. Biochim Biophys Acta 1436: 151-164.
4. Andjelkovic M, Jakubowicz T, Cron P, Ming XF, Han JW, Hemmings BA, (1996). Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. Proc Natl Acad Sci U S A 93: 5699-5704.
5. Barnes PJ, (2009a). The cytokine network in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 41: 631-638.
6. Barnes PJ, (2009b). Histone deacetylase-2 and airway disease. Ther Adv Respir Dis 3: 235-243.
7. Barnes PJ, Adcock IM, (2009). Glucocorticoid resistance in inflammatory diseases. Lancet 373: 1905-1917.
8. Bertrand D, Bertrand S, Neveu E, Fernandes P, (2010). Molecular characterization of off-target activities of telithromycin: a potential role for nicotinic acetylcholine receptors. Antimicrob Agents Chemother 54: 5399-5402.
9. Cantley LC, Neel BG, (1999). New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 96: 4240-4245.
10. Charron CE, Chou PC, Coutts DJ, Kumar V, To M, Akashi K, et al. (2009). Hypoxia-inducible factor 1alpha induces corticosteroid-insensitive inflammation via reduction of histone deacetylase-2 transcription. J Biol Chem 284: 36047-36054.
11. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ, (2004). Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 200: 689-695.
12. Crosbie PA, Woodhead MA, (2009). Long-term macrolide therapy in chronic inflammatory airway diseases. Eur Respir J 33: 171-181.
13. Dahia PL, Aguiar RC, Alberta J, Kum JB, Caron S, Sill H, et al. (1999). PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies. Hum Mol Genet 8: 185-193.
14. Desaki M, Okazaki H, Sunazuka T, Omura S, Yamamoto K, Takizawa H, (2004). Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells: possible role in the signaling pathway that regulates nuclear factor-kappaB activation. Antimicrob Agents Chemother 48: 1581-1585.
15. Farrell DJ, Sader HS, Castanheira M, Biedenbach DJ, Rhomberg PR, Jones RN, (2010). Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates. Int J Antimicrob Agents 35: 537-543.
16. Feschenko MS, Stevenson E, Nairn AC, Sweadner KJ, (2002). A novel cAMP-stimulated pathway in protein phosphatase 2A activation. J Pharmacol Exp Ther 302: 111-118.
17. Ford PA, Durham AL, Russell RE, Gordon F, Adcock IM, Barnes PJ, (2010). Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest 137: 1338-1344.
18. Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH, (2000). Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest 118: 1826-1827.
19. Gotfried MH, Jung R, Messick CR, Rubinstein I, Garey KW, Rodvold KA, et al. (2004). Effects of six-week clarithromycin therapy in corticosteroid- dependent asthma: a randomized, double-blind, placebo-controlled pilot study. Curr Ther Res 65: 1-12.
20. He ZY, Ou LM, Zhang JQ, Bai J, Liu GN, Li MH, et al. (2010). Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration 80: 445-452.
21. Hollander C, Sitkauskiene B, Sakalauskas R, Westin U, Janciauskiene SM, (2007). Serum and bronchial lavage fluid concentrations of IL-8, SLPI, sCD14 and sICAM-1 in patients with COPD and asthma. Respir Med 101: 1947-1953.
22. Ito K, Barnes PJ, (2009). COPD as a disease of accelerated lung aging. Chest 135: 173-180.
23. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, et al. (2005). Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 352: 1967-1976.
24. Ito K, Caramori G, Adcock IM, (2007). Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease. J Pharmacol Exp Ther 321: 1-8.
25. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
26. Knobloch J, Hag H, Jungck D, Urban K, Koch A, (2011). Resveratrol impairs the release of steroid-resistant cytokines from bacterial endotoxin-exposed alveolar macrophages in chronic obstructive pulmonary disease. Basic Clin Pharmacol Toxicol 109: 138-143.
27. Kobayashi Y, Mercado N, Barnes PJ, Ito K, (2011). Defects of protein phosphatase 2A causes corticosteroid insensitivity in severe asthma. PLoS ONE 6: e27627.
28. Kobayashi Y, Mercado N, Miller-Larsson A, Barnes PJ, Ito K, (2012). Increased corticosteroid sensitivity by a long acting beta2 agonist formoterol via beta2 adrenoceptor independent protein phosphatase 2A activation. Pulm Pharmacol Ther 25: 201-207.
29. Kobayashi Y, Wada H, Rossios C, Takagi D, Higaki M, Mikura S, et al. (2013). A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-κB inhibition. J Pharmacol Exp Ther 345: 76-84.
30. Lemaire S, Van Bambeke F, Tulkens PM, (2009). Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. Antimicrob Agents Chemother 53: 3734-3743.
31. Leslie NR, Bennett D, Lindsay YE, Stewart H, Gray A, Downes CP, (2003). Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J 22: 5501-5510.
32. Llano-Sotelo B, Dunkle J, Klepacki D, Zhang W, Fernandes P, Cate JH, Mankin AS, (2010). Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis. Antimicrob Agents Chemother 54: 4961-4970.
33. Marwick JA, Caramori G, Stevenson CS, Casolari P, Jazrawi E, Barnes PJ, et al. (2009). Inhibition of PI3Kdelta restores glucocorticoid function in smoking-induced airway inflammation in mice. Am J Respir Crit Care Med 179: 542-548.
34. Marwick JA, Caramori G, Casolari P, Mazzoni F, Kirkham PA, Adcock IM, et al. (2010). A role for phosphoinositol 3-kinase delta in the impairment of glucocorticoid responsiveness in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 125: 1146-1153.
35. McGhee P, Clark C, Kosowska-Shick KM, Nagai K, Dewasse B, Beachel L, et al. (2010). In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. Antimicrob Agents Chemother 54: 230-238.
36. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
37. Mercado N, To Y, Ito K, Barnes PJ, (2011a). Nortriptyline reverses corticosteroid insensitivity by inhibition of phosphoinositide-3-kinase-delta. J Pharmacol Exp Ther 337: 465-470.
38. Mercado N, To Y, Kobayashi Y, Adcock IM, Barnes PJ, Ito K, (2011b). p38 mitogen-activated protein kinase-gamma inhibition by long-acting beta2 adrenergic agonists reversed steroid insensitivity in severe asthma. Mol Pharmacol 80: 1128-1135.
39. Mercado N, Hakim A, Kobayashi Y, Meah S, Usmani OS, Chung KF, et al. (2012). Restoration of corticosteroid sensitivity by p38 mitogen activated protein kinase inhibition in peripheral blood mononuclear cells from severe asthma. PLoS ONE 7: e41582.
40. Milstone AP, (2008). Use of azithromycin in the treatment of acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis 3: 515-520.
41. Nakamaru Y, Vuppusetty C, Wada H, Milne JC, Ito M, Rossios C, et al. (2009). A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J 23: 2810-2819.
42. Osoata GO, Yamamura S, Ito M, Vuppusetty C, Adcock IM, Barnes PJ, et al. (2009). Nitration of distinct tyrosine residues causes inactivation of histone deacetylase 2. Biochem Biophys Res Commun 384: 366-371.
43. Paone G, Conti V, Vestri A, Leone A, Puglisi G, Benassi F, et al. (2011). Analysis of sputum markers in the evaluation of lung inflammation and functional impairment in symptomatic smokers and COPD patients. Dis Markers 31: 91-100.
44. Parnham MJ, (2005). Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 18: 125-131.
45. Pomares X, Monton C, Espasa M, Casabon J, Monso E, Gallego M, (2011). Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations. Int J Chron Obstruct Pulmon Dis 6: 449-456.
46. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. (2007). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176: 532-555.
47. Rodvold KA, Gotfried MH, Still JG, Clark K, Fernandes P, (2012). Comparison of plasma, epithelial lining fluid, and alveolar macrophage concentrations of solithromycin (CEM-101) in healthy adult subjects. Antimicrob Agents Chemother 56: 5076-5081.
48. Rossios C, To Y, Osoata G, Ito M, Barnes PJ, Ito K, (2012). Corticosteroid insensitivity is reversed by formoterol via phosphoinositide-3- kinase inhibition. Br J Pharmacol 167: 775-786.
49. Takizawa H, Desaki M, Ohtoshi T, Kikutani T, Okazaki H, Sato M, et al. (1995). Erythromycin suppresses interleukin 6 expression by human bronchial epithelial cells: a potential mechanism of its anti-inflammatory action. Biochem Biophys Res Commun 210: 781-786.
50. Takizawa H, Desaki M, Ohtoshi T, Kawasaki S, Kohyama T, Sato M, et al. (1997). Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med 156: 266-271.
51. To Y, Ito K, Kizawa Y, Failla M, Ito M, Kusama T, et al. (2010). Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 182: 897-904.
52. Tsai SC, Seto E, (2002). Regulation of histone deacetylase 2 by protein kinase CK2. J Biol Chem 277: 31826-31833.